What is the recommended dose of Vertine (betahistine) tablets for a patient with vertigo?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Betahistine (Vertine) Dosing for Vertigo

The standard dose of betahistine for vertigo is 48 mg daily, typically divided as 16 mg three times daily or 24 mg twice daily, with treatment duration of at least 3 months to evaluate efficacy. 1, 2

Standard Dosing Regimen

  • Start with 48 mg daily (16 mg three times daily or 24 mg twice daily), which can also be given as a single 48 mg modified-release formulation 1, 2
  • Minimum treatment duration is 3 months to properly assess therapeutic response 1, 2
  • Reassess at 6-9 months; if no improvement occurs after this period, discontinue betahistine as continued therapy is unlikely to provide benefit 1, 2, 3

Evidence Quality and Limitations

The evidence for betahistine is mixed and context-dependent. The American Academy of Otolaryngology-Head and Neck Surgery explicitly states they cannot make a definitive recommendation for betahistine in controlling Ménière's disease symptoms due to conflicting evidence from high-quality trials. 2 The BEMED trial found no significant difference between betahistine and placebo in reducing vertigo attacks over 9 months. 2 However, older studies and a 2016 Cochrane review suggested a 56% reduction in vertigo with betahistine versus placebo. 3

Primary Indication

  • Betahistine is primarily indicated for Ménière's disease as maintenance therapy to reduce frequency and severity of vertigo attacks 1, 3
  • Definite Ménière's disease requires 2 or more episodes of vertigo lasting 20 minutes to 12 hours AND fluctuating or nonfluctuating sensorineural hearing loss, tinnitus, or pressure in the affected ear 1
  • Not recommended as first-line treatment for benign paroxysmal positional vertigo (BPPV), where canal repositioning maneuvers are superior (78.6-93.3% improvement vs 30.8% with medication alone) 1, 4

Dosing Considerations

  • Higher doses (144 mg/day) have not shown significant improvement compared to standard 48 mg/day dosing 1, 2
  • Meta-analysis data suggests maximum efficacy occurs with doses of 32-36 mg daily over 3-8 weeks of treatment 5
  • Research studies have used 16 mg three times daily (48 mg total) with significant improvement in frequency, duration, and severity of vertigo attacks 6

Absolute Contraindications

  • Pheochromocytoma is an absolute contraindication 1, 2, 3

Relative Contraindications and Cautions

  • Use with caution in patients with asthma 1, 2, 3
  • Use with caution in patients with history of peptic ulcer disease 1, 2, 3

Common Side Effects

  • Headache, balance disorder, nausea, and upper gastrointestinal symptoms 1, 2, 3
  • Nasopharyngitis, feeling hot, eye irritation, and palpitations 2
  • Serious medical side effects are rare 2

Monitoring Parameters

  • No routine laboratory monitoring is required due to betahistine's excellent safety profile over 40 years of clinical use 1, 3
  • Track changes in vertigo frequency and severity, tinnitus, hearing loss, and aural fullness 1

Important Clinical Pitfalls

Do not use betahistine for acute vertigo attacks. For acute episodes, vestibular suppressants (benzodiazepines, antihistamines like meclizine, or promethazine) should be used for short-term symptom control only. 4, 3 Betahistine is maintenance therapy, not acute treatment. 1, 3

Do not prescribe vestibular suppressants for BPPV except for short-term management of severe nausea or vomiting, as they are ineffective as primary treatment and interfere with central compensation. 4

Avoid concurrent initiation of betahistine with prochlorperazine as this makes it difficult to assess individual medication efficacy and increases risk of orthostatic hypotension, dizziness, and sedation without proven additional benefit. 1

References

Guideline

Vestibular Disorder Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Betahistine Dosing for Meniere's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Meniere's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Betahistine in the treatment of vertiginous syndromes: a meta-analysis.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2006

Research

Management of acute vertigo with betahistine.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2000

Related Questions

What is the standard dosing of betahistine (Histamine receptor agonist) for a patient with Benign Paroxysmal Positional Vertigo (BPPV)?
What is the typical duration of treatment with Vertin (Betahistine) for vertigo?
What is the recommended dosage and treatment approach for vertigo using betahistine (etahistine dihydrochloride)?
What is the recommended dosing for Betahistine (Betahistine) in a patient with vertigo?
What are the potential interactions between betahistine (histamine H1 receptor agonist) and clonazepam (benzodiazepine) in an adult patient with a history of vertigo or inner ear disorders and possibly anxiety or seizure disorders?
What is the recommended dosage and administration of Nexium (Esomeprazole) for an 8-month-old, 9.8kg infant with Gastroesophageal Reflux Disease (GERD)?
What is the recommended treatment approach for an adult patient with diabetes using Ryzodeg (insulin degludec and insulin aspart)?
What is the appropriate diagnosis and treatment plan for a patient with elevated Adrenocorticotropic hormone (ACTH), hypercortisolism, euthyroid status, and normal sodium levels?
What are the treatment guidelines for a patient with metastatic melanoma?
What are the next steps for an adult patient with an abnormal Serum Protein Electrophoresis (SPEP) result, possibly indicating multiple myeloma or lymphoma, and presenting with symptoms such as anemia, bone pain, or recurrent infections?
What is the recommended treatment and management approach for a patient with a suspected Phyllodes tumor of the breast?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.